Fmr LLC cut its stake in shares of TherapeuticsMD Inc (NASDAQ:TXMD) by 0.5% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 29,340,231 shares of the company’s stock after selling 146,800 shares during the period. Fmr LLC owned approximately 14.39% of TherapeuticsMD worth $211,250,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Greenwood Capital Associates LLC boosted its position in TherapeuticsMD by 17.5% in the first quarter. Greenwood Capital Associates LLC now owns 20,309 shares of the company’s stock valued at $146,000 after buying an additional 3,022 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its position in TherapeuticsMD by 56.1% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 28,730 shares of the company’s stock valued at $207,000 after buying an additional 10,330 shares in the last quarter. American International Group Inc. boosted its position in TherapeuticsMD by 7.1% in the first quarter. American International Group Inc. now owns 92,415 shares of the company’s stock valued at $665,000 after buying an additional 6,103 shares in the last quarter. Stifel Financial Corp boosted its position in TherapeuticsMD by 125.4% in the first quarter. Stifel Financial Corp now owns 429,362 shares of the company’s stock valued at $3,091,000 after buying an additional 238,885 shares in the last quarter. Finally, Sphera Funds Management LTD. bought a new position in TherapeuticsMD during the first quarter valued at $4,176,000.

Institutional Ownership by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Shares of TherapeuticsMD Inc (TXMD) traded up 19.42% on Friday, hitting $5.35. 8,168,165 shares of the stock traded hands. TherapeuticsMD Inc has a 52 week low of $3.50 and a 52 week high of $8.88. The stock’s market cap is $1.09 billion. The stock has a 50 day moving average price of $4.37 and a 200-day moving average price of $5.66.

COPYRIGHT VIOLATION NOTICE: This news story was published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.watchlistnews.com/therapeuticsmd-inc-txmd-shares-sold-by-fmr-llc/1372345.html.

TXMD has been the topic of several research analyst reports. Stifel Nicolaus reissued a “buy” rating and issued a $20.00 price target on shares of TherapeuticsMD in a report on Monday, April 24th. Jefferies Group LLC set a $15.00 price target on shares of TherapeuticsMD and gave the company a “buy” rating in a report on Wednesday. Zacks Investment Research raised shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Friday, May 12th. CIBC reissued a “market perform” rating and issued a $12.00 price target on shares of TherapeuticsMD in a report on Tuesday, May 9th. Finally, Oppenheimer Holdings, Inc. cut shares of TherapeuticsMD from an “outperform” rating to a “market perform” rating and set a $12.00 target price on the stock. in a report on Tuesday, May 9th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $18.40.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Want to see what other hedge funds are holding TXMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TherapeuticsMD Inc (NASDAQ:TXMD).

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.